US20150306214A1 - Adjuvant for mucosal vaccine - Google Patents
Adjuvant for mucosal vaccine Download PDFInfo
- Publication number
- US20150306214A1 US20150306214A1 US14/649,279 US201314649279A US2015306214A1 US 20150306214 A1 US20150306214 A1 US 20150306214A1 US 201314649279 A US201314649279 A US 201314649279A US 2015306214 A1 US2015306214 A1 US 2015306214A1
- Authority
- US
- United States
- Prior art keywords
- viruses
- adjuvant
- amino acid
- antigens
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract description 119
- 229960005486 vaccine Drugs 0.000 title claims abstract description 106
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 62
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 41
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 41
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 41
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 41
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 41
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 15
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 12
- 239000000427 antigen Substances 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 94
- 102000036639 antigens Human genes 0.000 claims description 94
- 206010022000 influenza Diseases 0.000 claims description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 244000052616 bacterial pathogen Species 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 206010065764 Mucosal infection Diseases 0.000 claims description 7
- 238000007792 addition Methods 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241000588832 Bordetella pertussis Species 0.000 claims description 3
- 201000006082 Chickenpox Diseases 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 3
- 241000710829 Dengue virus group Species 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000710843 Japanese encephalitis virus group Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 206010046980 Varicella Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 abstract description 8
- 230000028993 immune response Effects 0.000 abstract description 7
- 235000018102 proteins Nutrition 0.000 description 48
- 238000002649 immunization Methods 0.000 description 28
- 230000003053 immunization Effects 0.000 description 28
- 108010058846 Ovalbumin Proteins 0.000 description 23
- 229940092253 ovalbumin Drugs 0.000 description 23
- 102000009016 Cholera Toxin Human genes 0.000 description 19
- 108010049048 Cholera Toxin Proteins 0.000 description 19
- 210000003928 nasal cavity Anatomy 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000013566 allergen Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 108010021466 Mutant Proteins Proteins 0.000 description 10
- 102000008300 Mutant Proteins Human genes 0.000 description 10
- 230000000240 adjuvant effect Effects 0.000 description 9
- 230000015788 innate immune response Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 101710138657 Neurotoxin Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229940039412 ketalar Drugs 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 230000031998 transcytosis Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000017306 interleukin-6 production Effects 0.000 description 3
- 210000003126 m-cell Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 208000006373 Bell palsy Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 229940094657 botulinum toxin type a Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 210000001986 peyer's patch Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013573 pollen allergen Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- -1 IL-1β Proteins 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to an effective and safe adjuvant for a mucosal vaccine and a mucosal vaccine preparation containing such adjuvant and vaccine antigens.
- mucosal immunity In recent years, the mechanisms of mucosal immunity on the respiratory apparatus, the digestive apparatus, the reproductive organs, and other organs have been gradually elucidated as the immune system to prevent infectious diseases such as influenza or acquired immunodeficiency syndrome (AIDS).
- infectious diseases such as influenza or acquired immunodeficiency syndrome (AIDS).
- AIDS acquired immunodeficiency syndrome
- mucosal IgA antibody mucosal IgA antibody
- serum IgG antibody to neutralize the viruses
- cytotoxic T cells that lyse infected cells to interrupt virus transmission.
- mucosal immune mechanisms are functional at the initial phase of infection, and play a key role in biophylaxis at the time of infection or during the initial phase of infection.
- mucosal vaccines inducing immune protection response against infection on the mucosa which is the first barrier at portals of entry for pathogens, are considered as effective vaccine for various infectious diseases through mucosae.
- mucosal vaccines induce secretory IgA antibody in mucosal tissue upon mucosal administration (e.g., intranasal administration), and also induce IgG antibody in the serum.
- mucosal vaccines are capable of inducing immune responses in both the mucosal and systemic systems against pathogens.
- mucosal vaccines are superior to conventional vaccination with needles and syringe in terms of operability, safety, and economic efficiency. Accordingly, mucosal vaccines are expected as novel vaccines, and have been developed.
- mucosal adjuvants with toxins such as CT or LT might be difficult in terms of safety.
- MPL resulting from attenuation of activity of endotoxin LPS, bacterial flagellin proteins (Patent Document 1), double-stranded RNA (poly(I:C)) (Patent Document 2), and other substances have been studied as mucosal adjuvants, which are not derived from toxins.
- those candidates induce excessive inflammatory responses, they are not satisfactory for mucosal adjuvants in terms of safety. That is, no effective and safe adjuvants for mucosal vaccines are being put to practical use at present.
- hemagglutinin (HA) and the nontoxic-nonhemagglutinin (NTNH) component bind to the botulinum neurotoxin (NIX) produced by botulinum bacilli causing food poisoning, and those components form three types of neurotoxin complex (progenitor toxin (PTX)) whose molecular weight are 300,000, 500,000, or 900,000.
- PTX neurotoxin complex
- Botulinum toxin blocks neuron transmission, and leads to death in human. Taking advantage of the activity thereof, botulinum toxin is used as an effective neurotransmission inhibitor for medical purposes.
- a botulinum toxin type A (BOTOX) complex is known to be used for treatment of blepharospasm, hemifacial spasm, spasmodic torticollis, heterotropia, and the reduction of wrinkles.
- non-toxic HA is known to have functions of disrupting the epithelial barrier and transporting botulinum neurotoxins and macromolecules.
- NTX and albumin antigens are subcutaneously administered to mice in combination with HA, production of serum antibody specific for antigens is enhanced through IL-6 production (Non-Patent Document 3).
- Patent Documents 3 and 4 describe the adjuvant activity of an HA subcomponent (HA1 or HA3) and the use as a carrier of nucleic acids into cells, no protein complex composed of HA subcomponents (HA1, HA2, and HA3) has been discussed.
- the present inventors previously reported that HA acts on M cells in the epithelial cell layer of the Peyer's patch (i.e., M cells on the Peyer's patch), and that HA assists migration of neurotoxin complex from apical side of to basolateral side of M cells via transcytosis (Non-Patent Document 4).
- an object of the present invention is to provide an adjuvant for mucosal vaccines with high both efficacy and safety.
- the present inventors focused on hemagglutinin (HA), a non-toxic component of botulinum toxin, and the mice were intranasally immunized with a protein complex composed of HA subcomponents (HA1, HA2, and HA3) intranasal in combination with ovalbumin antigens or influenza HA antigens.
- HA hemagglutinin
- HA subcomponents HA1, HA2, and HA3
- the present invention includes the following.
- An adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin.
- HA hemagglutinin
- the adjuvant according to (1) or (2) which is used simultaneously with vaccine antigens or before or after vaccine antigens are administered.
- the adjuvant according to (3), wherein the vaccine antigens are subunit antigens or inactivated antigens.
- the adjuvant according to (3) or (4), wherein the vaccine antigens are derived from pathogens causing mucosal infections.
- the adjuvant according to (5), wherein the pathogens causing mucosal infections are viruses or bacteria.
- influenza viruses human immunodeficiency viruses (HIV), chickenpox viruses, measles viruses, rubella viruses, mumps viruses, polioviruses, rotaviruses, adenoviruses, herpes viruses, RS viruses, dengue viruses, Japanese encephalitis viruses, severe acute respiratory syndrome (SARS) viruses, or hepatitis viruses (type A, type B, or type C).
- influenza viruses human immunodeficiency viruses (HIV), chickenpox viruses, measles viruses, rubella viruses, mumps viruses, polioviruses, rotaviruses, adenoviruses, herpes viruses, RS viruses, dengue viruses, Japanese encephalitis viruses, severe acute respiratory syndrome (SARS) viruses, or hepatitis viruses (type A, type B, or type C).
- HAV human immunodeficiency viruses
- chickenpox viruses measles viruses
- rubella viruses rubella viruses
- mumps viruses polioviruses
- Neisseria meningitidis type B influenza, pneumococcus, tuberculosis bacteria, tetanus bacilli, or cholera bacilli.
- the adjuvant according to any of (1) to (8) which is administered with any mucosal routes.
- the adjuvant according to (9), wherein the administration with mucosal routes is intranasal administration.
- a mucosal vaccine preparation comprising vaccine antigens and the adjuvant according to any of (1) to (10).
- the adjuvant of the present invention When the adjuvant of the present invention is administered to mucosa such as the intranasal mucosa in combination with vaccine antigens derived from pathogens causing mucosal infections, such as influenza viruses, production of serum IgG antibody and that of secretory IgA antibody on the mucosa are accelerated, and antigen-specific systemic and mucosal immune responses are enhanced. Accordingly, the adjuvant of the present invention is useful as an adjuvant for a mucosal vaccine against diseases of the respiratory apparatus or the digestive apparatus.
- vaccine antigens derived from pathogens causing mucosal infections such as influenza viruses
- production of serum IgG antibody and that of secretory IgA antibody on the mucosa are accelerated, and antigen-specific systemic and mucosal immune responses are enhanced.
- the adjuvant of the present invention is useful as an adjuvant for a mucosal vaccine against diseases of the respiratory apparatus or the digestive apparatus.
- the adjuvant of the present invention uses hemagglutinin (HA) subcomponent, which is a non-toxic botulinum toxin component, the adjuvant does not activate innate immunity, and the adjuvant is less likely to cause inflammations on mucosa after administration. Therefore, the adjuvant of the present invention is very safe for mucosal vaccines to use.
- HA hemagglutinin
- FIG. 1 shows the amino acid sequence of recombinant botulinus HA1-3 used to prepare the botulinus HA (BHA) complex in Example 1.
- the underlined regions indicate vector-derived amino acid sequences (FLAG tag sequence: SEQ ID NO: 7; Strep tag sequence: SEQ ID NO: 8).
- FIG. 2 shows purification of the BHA complex via gel filtration chromatography.
- FIG. 3 shows interaction between M cells and each subcomponcnt HA1, HA2, or HA3 of botulinus (a microscope photograph showing localization of subcomponents on the follicle-associated epithelium (FAE)).
- FIG. 4 shows interaction between M cell and the HA2+3 complex or the HA1+2+3 complex of botulinus (a microscope photograph showing localization of complexes on the follicle-associated epithelium (FAE)).
- FIG. 5 shows the results of ELISA that measured the concentration of ovalbumin-specific IgG in sera and that of ovalbumin-specific IgA in the nasal cavity lavage or in the bronchoalveolar lavage (OVA: the group to which ovalbumin alone is administered; OVA+CTB: the group to which ovalbumin with the cholera toxin B subunit are administered; OVA+BHA: the group to which ovalbumin with the BHA complex are administered; Reciprocal log 2 titer: the antibody titer represented by the logarithm of the reciprocal of the maximal dilution factor exhibiting absorbance that is higher than the sample before immunization by 0.1).
- OVA the group to which ovalbumin alone is administered
- OVA+CTB the group to which ovalbumin with the cholera toxin B subunit are administered
- OVA+BHA the group to which ovalbumin with the BHA complex are administered
- Reciprocal log 2 titer the antibody titer represented by the
- FIG. 6 shows activation of innate immunity by the BHA complex (the amount of IL-6 produced).
- FIG. 7 shows the results of ELISA that measured the concentration of influenza-antigen-specific IgG in the sera (SV: the group to which influenza split vaccine alone is administered; SV+BHA: the group to which influenza split vaccine with BHA complex are administered; SV+CTB: the group to which influenza split vaccine with cholera toxin B subunit are administered; NC: the group to which no antigens with adjuvants is administered (*** p ⁇ 0.0001 ** p ⁇ 0.001 * p ⁇ 0.01)).
- FIG. 8 shows the results of ELISA that measured the concentration of influenza-antigen-specific IgA in the nasal cavity lavage and in the bronchoalveolar lavage (SV: the group to which influenza split vaccine alone is administered; SV+BHA: the group to which influenza split vaccine with BHA complex are administered; SV+CTB: the group to which influenza split vaccine with cholera toxin B subunit are administered: NC: the group to which no antigens with adjuvants is administered (*** p ⁇ 0.0001 ** p ⁇ 0.001 * p ⁇ 0.01)).
- FIG. 9 shows the results of ELISA that measured the concentration of influenza-antigen-specific IgG in the sera
- SV the group to which influenza split vaccine alone is administered
- SV+BHA the group to which influenza split vaccine with BHA complex are administered
- SV+BHA1-3 the group to which influenza split vaccine with BHA1, BHA2, or BHA3 are administered
- SV+CTB the group to which influenza split vaccine with cholera toxin B subunit are administered: NC: the group to which no antigens with adjuvants is administered (*** p ⁇ 0.0001 ** p ⁇ 0.001 * p ⁇ 0.01)).
- FIG. 10 shows the results of ELISA that measured the concentration of influenza-antigen-specific IgA in the nasal cavity lavage and in the bronchoalveolar lavage
- SV the group to which influenza split vaccine alone is administered
- SV+BHA the group to which influenza split vaccine with BHA complex are administered
- SV+BHA1-3 the group to which influenza split vaccine with BHA1, BHA2, or BHA3 are administered
- SV+CTB the group to which influenza split vaccine with cholera toxin B subunit are administered: NC: the group to which no antigens with adjuvants is administered (*** p ⁇ 0.0001 ** p ⁇ 0.001 * p ⁇ 0.01)).
- the adjuvant for a mucosal vaccine of the present invention (hereafter it is merely referred to as an “adjuvant”) is a protein complex composed of HA1, HA2, and HA3, which are hemagglutinin (HA) subcomponents of botulinum toxin.
- HA hemagglutinin
- the term “adjuvant” used herein refers to a substance that is administered so as to enhance the immunogenicity of a vaccine antigen.
- Botulinum toxins are classified as type A to type G in accordance with the different antigenicities of toxins produced by botulinum bacilli ( Clostridium botulinum ).
- the botulinum toxin complex for the adjuvant of the present invention is preferably of type A or type B.
- the first component of the protein complex contained in the adjuvant of the present invention is the botulinum toxin complex HA1
- the second component is the botulinum toxin complex HA2
- the third component is the botulinum toxin complex HA3.
- HA1, HA2, and HA3 are a protein consisting of the amino acid sequence as shown in SEQ ID NO: 1, a protein consisting of the amino acid sequence as shown in SEQ ID NO: 2, and a protein consisting of the amino acid sequence as shown in SEQ ID NO: 3, respectively.
- the adjuvant of the present invention is preferably a protein complex composed of the first component, the second component, and the third component.
- the three proteins composing the protein complex may be mutant proteins of the protein consisting of the amino acid sequence as shown in SEQ ID NO: 1, the protein consisting of the amino acid sequence as shown in SEQ ID NO: 2, and the protein consisting of the amino acid sequence as shown in SEQ ID NO: 3, respectively, provided that such mutant proteins have activities equivalent to those of the relevant original proteins.
- mutant proteins “have activities equivalent to” those of the original proteins
- the protein complex composed of such mutant proteins has mucosal adjuvant activity equivalent to that of the protein complex composed of the protein consisting of the amino acid sequence as shown in SEQ ID NO: 1, the protein consisting of the amino acid sequence as shown in SEQ ID NO: 2, and the protein consisting of the amino acid sequence as shown in SEQ ID NO: 3.
- mutant protein refers to activity that enhances production of antigen-specific antibody when the adjuvant is administered transmucosally in combination with vaccine antigens in both the mucosal and systemic immune response.
- the influence of such activity on innate immunity is insignificant, and production of antigen-specific antibody is enhanced in both the mucosal and systemic immunity.
- innate immunity is not influenced and production of antigen-specific antibody is enhanced in both the mucosal and systemic immunity.
- An example of such mutant protein is a protein consisting of an amino acid sequence derived from the amino acid sequence as shown in SEQ ID NO: 1, 2, or 3 by deletion, substitution, insertion, or addition of one to several amino acids.
- a mutant protein may consist of an amino acid sequence having 90% or higher identity to the amino acid sequence as shown in SEQ ID NO: 1, 2, or 3.
- the term “90% or higher identity” used herein refers to sequence identity of preferably 95% or higher, more preferably 97% or higher, and most preferably 98% or higher. Amino acid sequence identity can be determined by FASTA or BLAST search. While the term “mutation” used herein primarily refers to a mutation that is artificially introduced in accordance with a known method of producing a mutant protein, an equivalent mutation existing in nature may be employed.
- a method for producing the adjuvant of the present invention is not particularly limited.
- the protein complex may be derived from nature.
- proteins composing such protein complex may be produced via a genetic recombination technique, and the protein complex may be formulated using such proteins.
- the protein complex may be produced in accordance with a conventional genetic recombination technique using genes encoding the proteins of interest.
- HA1, HA2, and HA3 can be produced by constructing expression vectors containing genes encoding the amino acid sequences as shown in SEQ ID NOs: 1, 2, and 3 (the nucleotide sequences are shown in SEQ ID NOs: 4, 5, and 6, respectively), introducing the expression vectors into adequate host cells, and culturing the host cells. Mutant proteins of HA1.
- HA2, and HA3 can be also produced by a well-known recombinant DNA technique by, for example, subjecting genes encoding the amino acid sequences as shown in SEQ ID NOs: 1, 2, and 3 to site-directed mutagenesis, obtaining genes encoding the mutant proteins, and using such genes.
- the protein productions can be easily carried out with reference to, for example. Molecular Cloning 2nd Ed., Cold Spring Harbor Laboratory Press, 1989.
- HA1, HA2, and HA3 can be chemically synthesized on the basis of the amino acid sequences thereof.
- the resulting HA1. HA2, and HA3 proteins may be incubated in a solvent such as a phosphate buffer for 2 to 8 hours, preferably 3 to 5 hours, and more preferably 3 hours at 25° C. to 40° C. and preferably 37° C. and the protein complex may be thus composed.
- a fusion protein may be prepared from the HA1, HA2, and HA3 proteins.
- the adjuvant of the present invention may be administered to organisms simultaneously with vaccine antigens.
- the adjuvant may be administered before the administration of vaccine antigens or after the administration of antigens.
- the adjuvant may be administered substantially simultaneously with the vaccines.
- the adjuvant and vaccine antigens may be administered to the target at exactly the same time, or they may be continuously administered within a given period of time (preferably within several minutes).
- the vaccine antigens are preferably inactivated antigens or subunit antigens.
- the term “inactivated antigens” refers to antigens of pathogens (e.g., viruses or bacteria) deprived of infectivity. Examples thereof include complete virus particles (virions), incomplete virus particles, virion-constituting particles, virus nonstructural proteins, the antigens to prevent infections, and neutralizing epitopes.
- Antigens may be inactivated by physical treatments (e.g., x-rays, heat, or ultrasound), chemical treatments (e.g., formalin, mercury, alcohol, or chlorine), or via other means.
- subunit vaccines refers to vaccines selectively containing particular antigens (i.e., the antigens to prevent infections) that are effective vaccine components among various types of antigens contained in inactivated vaccines.
- An example of a subunit vaccine against the influenza virus is a vaccine selectively containing hemagglutinin (HA) and neuraminidase (NA) that are surface antigens purified.
- HA hemagglutinin
- NA neuraminidase
- the vaccine antigens are not particularly limited, provided that the vaccine antigens are capable of inducing a mucosal immune response together with the adjuvant of the present invention.
- Typical antigens are derived from pathogens causing mucosal infections. Pathogens causing mucosal infections may be viruses or bacteria.
- viruses include, but are not limited to, influenza viruses, human immunodeficiency viruses (HIV), chickenpox viruses, measles viruses, rubella viruses, mumps viruses, polioviruses, rotaviruses, adenoviruses, herpes viruses, RS viruses, dengue viruses, Japanese encephalitis viruses, severe acute respiratory syndrome (SARS) viruses, and hepatitis viruses (type A, type B, and type C).
- bacteria include, but are not limited to, Bordetella pertussis, Neisseria meningitidis , type B influenza, pneumococcus, tuberculosis bacteria, tetanus bacilli, and cholera bacilli.
- antigens derived from pathogens may be derived from nature or artificially prepared via gene recombination or other techniques.
- the vaccine antigens include allergens used for hyposensitization therapy. Accordingly, the adjuvant of the present invention can be used as an adjuvant for allergen vaccines. Allergen vaccines are used to block IgE causing allergies by producing IgG antibody against allergens or to increase allergen-specific type I helper T cells (Th1 cells) in vivo by administering allergens to organisms, thereby decreasing type II helper T cells (Th2 cells) associated with allergy symptoms. Allergen vaccines are capable of suppressing allergy symptoms via hyposensitization.
- allergens are not particularly limited, and examples of allergens include food allergens (e.g., casein, lactalbumin, lactoglobulin, ovomucoid, ovalbumin, and conalbumin), house dust allergens (e.g., mite allergens), pollen allergens (e.g., cedar pollen allergens, ragweed allergens, and cocksfoot grass allergens), and allergens of animal body hair.
- food allergens e.g., casein, lactalbumin, lactoglobulin, ovomucoid, ovalbumin, and conalbumin
- house dust allergens e.g., mite allergens
- pollen allergens e.g., cedar pollen allergens, ragweed allergens, and cocksfoot grass allergens
- allergens of animal body hair e.g., casein, lactalbumin, lactoglobulin, ovomucoid
- the adjuvant of the present invention is administered transmucosally in combination with the mucosal vaccine antigens.
- an agent is “administered transmucosally,” it is administered through the mucosa.
- mucosae include inner walls of hollow organs that lead to the exterior, such as the digestive apparatus, the respiratory apparatus, and the urogenital apparatus, and specific examples include the nasal cavity, oral cavity, pharynx, alveolus, air tube, intestinal tract, and vagina, with the nasal cavity being preferable.
- examples of forms of transmucosal administration include intranasal, intraoral, intra-alveolar, intratracheal, intravaginal, and intrarectal administration with the intranasal administration being preferable.
- Adjuvants and mucosal vaccines can be administered transmucosally in an adequate manner in accordance with the site of administration.
- the agents can be sprayed, added dropwise, or applied to the nasal cavity or oral cavity.
- Intra-alveolar administration can be carried out by a method involving the use of an inhaler or a sprayer or a method of administering a preparation comprising an aerosol preparation.
- the amount of the adjuvant of the present invention to be administered varies in accordance with the age of the subject, body weight, disease type, route of administration, form of administration, and other conditions.
- oral administration for example, 10 ⁇ g to 100 mg, and preferably 1 ⁇ g to 10 mg of the adjuvant of the present invention can be administered simultaneously with vaccine antigens per instance per adult human.
- nasal administration 0.1 ⁇ g to 100 mg, and preferably 1 ⁇ g to 10 mg of the adjuvant can be administered, for example.
- Subjects of administration can be adequately determined in accordance with the types of vaccine antigens used in combination with the adjuvant. Examples thereof include, in addition to humans, non-human mammalians, birds, and crustaceans.
- a person skilled in the art can easily determine the frequency of administration of the adjuvant of the present invention in combination with vaccine antigens to the subjects by taking, for example, age, body weight, medical history, clinical course of the subject, disease type, and other factors into consideration.
- administration may be carried out at an adequate time before the onset of the disease at the frequency of, in general, one to several instances per day for a day, or administration may be carried out several times at intervals of one to several weeks.
- Administration is preferably carried out while observing progress, and booster immunization is preferably carried out at intervals of at least a week. Intervals of booster immunization are preferably at least about two weeks. By providing booster immunization, more effective infection-protective effects can be expected.
- the adjuvant may be mixed with vaccine antigens together with pharmaceutically acceptable carriers suitable for the dosage form, and vaccine preparations may be produced by various known techniques.
- the amount of the adjuvant to be incorporated into vaccine preparations can be adequately determined in accordance with the types of vaccine antigens to be mixed.
- the content of the adjuvant in the preparations is not particularly limited, provided that sufficient antigen immune responses are induced via transmucosal administration.
- Such amount is generally 0.1% to 90% by weight, preferably 0.5% to 80% by weight, and more preferably 1% to 50% by weight relative to the entire preparation amount.
- Dosage forms of the mucosal vaccine preparations of the present invention are not particularly limited, provided that the mucosal vaccine preparations can be administered transmucosally. Examples thereof include liquid preparations, suspensions, sprays, and powders. According to need, various additives that are generally used for vaccine preparations, such as solubilizers, anticoagulants, viscosity modifiers, pH adjusters, isotonizing agents, emulsifiers, antioxidants, fillers, surfactants, diluents, preservatives, stabilizers, desiccating agents, or moisturizing agents, can be added to the mucosal vaccine preparations of the present invention.
- solubilizers such as solubilizers, anticoagulants, viscosity modifiers, pH adjusters, isotonizing agents, emulsifiers, antioxidants, fillers, surfactants, diluents, preservatives, stabilizers, desiccating agents, or moisturizing agents.
- the vaccine preparations of the present invention can be in a liquid state or a dried state, and such vaccine preparations can be introduced into hermetically sealed vial bottles, syringes, atomizers, or scaled ampules.
- the botulinus HA (BHA) complex was prepared in the manner described below.
- BHA1, BHA2, and BHA3 The genes encoding the proteins of the botulinus HA subcomponents (BHA1, BHA2, and BHA3) (BHA1: a protein consisting of amino acids 7 to 294 of the amino acid sequence as shown in SEQ ID NO: 1; BHA2: a protein consisting of amino acids 2 to 146 of the amino acid sequence as shown in SEQ ID NO: 2; and BHA3: a protein consisting of amino acids 19 to 626 of the amino acid sequence as shown in SEQ ID NO: 3) were amplified by PCR from genomic DNA of the Clostridium botulinum B-Okra strain as a template using the primers described below.
- BHA1 forward primer cactataagcttatccaaaattcattaaatg
- BHA1 reverse primer gttgataggtaccttatgggttactcatag
- BHA forward primer (SEQ ID NO: 11) tgaataagctttcagctgaaagaacttttc
- BHA2 reverse primer (SEQ ID NO: 12) cactttggtaccttatattttttcaagtttga
- BHA3 forward primer (SEQ ID NO: 13) gaaaaagggtaccaatatagtgatactattg
- BHA3 reverse primer (SEQ ID NO: 14) cgtgtcgacttaattagtaatatctatatgc
- the amplified DNA fragments of BHA1 and BHA2 were each inserted into the HindIII-SalI site of pT7-FLAG-1 (Sigma), and the amplified DNA fragment of BHA3 was inserted into the KpnI-SalI site of pET52b(+) (Novagen) (pET-BHA3).
- E. coli Rosetta2 (DE3) strains (Novagen). Protein expression was induced using the Overnight Express Autoinduction System 1 (Novagen). BHA1 and BHA3 were induced to express proteins at 30° C. for 36 hours, and BHA2 was induced to express a protein at 18° C. for 40 hours. E. coli strains were collected by centrifugation and stored at ⁇ 80° C.
- BHA1 and BHA2 were purified using Anti-FLAG M2 agarose (Sigma).
- BHA3 was purified using StrepTrap HP (GE Healthcare).
- the amino acid sequences of the purified recombinant proteins. FLAG-BHA1, FLAG-BHA2, and Strep-BHA3, are shown in FIG. 1 .
- the purified recombinant proteins were mixed at a ratio of BHA1:BHA2:BHA3 of 4:4:1 by mole, and the resultant was incubated at 37° C. for 3 hours, followed by purification with the use of StrepTrap HP.
- BHA BHA complex
- the BHA complex (BHA) prepared in Example 1 was separated using Superdex 200 10/300 GL (GE Healthcare). In this test, C-terminal FLAG tag HA1, N-terminal His tag HA2, and N-terminal Strep tag HA3 were used for HA1, HA2, and HA3 composing the BHA complex (BHA). The results are shown in FIG. 2 .
- HA1, HA2, and HA3 of botulinus type A were labeled with Alexa 568 and injected into ligated intestinal loop of the mouse. Two hours later, HA subcomponent localization was observed under a confocal microscope. M cells were stained with FITC-labeled UEA-1. Neither M-cell binding nor transcytosis was substantially observed as a result when HA1, HA2, or HA3 alone was used ( FIG. 3 ).
- the HA213 complex and the HA1+2+3 complex of botulinus type A were labeled with Alexa 568 and injected into ligated intestinal loop of the mouse. Two hours later, localization of complexes was observed under a confocal microscope. M cells were stained with FITC-labeled UEA-1. Neither M-cell binding nor transcytosis was substantially observed as a result when the HA2+3 complex was used. As with the case of native 16S toxin. M-cell binding and transcytosis were observed when the HA1+2+3 complex was used ( FIG. 4 ). Thus, formation of a complex of HA1, HA2, and HA3 was found to be necessary for interaction between M cell and HA.
- the amount of IL-6 cytokine production resulting from treatment with the BHA complex adjuvant was measured using mouse splenocytes, and the ability of the BHA complex adjuvant to activate innate immunity was evaluated.
- Splenocytes were sampled from native mice raised under SPF conditions (C57BL/6, 6-week-old, female, purchased from CLEA Japan. Inc.) and seeded onto a 96-well plate at a cell density of 1 ⁇ 10 6 cells/well. Thereafter, the BHA complex (BHA) was serially diluted from 20 ⁇ g/ml (20 ⁇ g/ml, 2 ⁇ g/ml. 0.2 ⁇ g/ml), and the splenocytes were stimulated. The splenocytes were further stimulated with the BHA complex adjuvant in combination with a TLR ligand of CpG oligo DNA (K3 or D35, 20 ⁇ g/ml) or LPS (1 ⁇ g/ml).
- BHA BHA complex
- the culture supernatant was recovered 24 hours after the initiation of stimulation and the amount of cytokine (IL-6) in the culture supernatant was measured (R&D systems).
- the results are shown in FIG. 6 .
- the induction of IL-6 by the BHA complex adjuvant alone was below the detection limit.
- the amounts of TNF- ⁇ , IL-1 ⁇ , and IL-12 were also below the detection limit. Since the BHA complex adjuvant would not influence IL-6 production mediated by CpG or LPS stimulation, it was considered that the BHA complex adjuvant would not enhance or suppress signals to activate any other innate immunity. Thus, the BHA complex adjuvant was considered to be a non-inflammatory adjuvant that would not influence signals to activate innate immunity.
- Influenza split vaccines were used as antigens to evaluate adjuvant effects of the BHA complex.
- mice and C57BL/6 mice (6-week-old, female) were purchased from CLEA Japan, Inc. Mice were raised under SPF conditions.
- split vaccines The mouse-adapted A/Puerto Rico/8/34 (H1N1) split vaccines (hereafter referred to as “split vaccines”) received from Kitasato Daiichi Sankyo Vaccine Co., Ltd. were used as vaccine antigens. During the experiment, antigens were refrigerated at 4° C. in the dark.
- the BHA complex (BHA) prepared in Example 1 was used as the adjuvant. Endotoxin content was determined by designating the standard for purification at 0.5 EU/ml or lower.
- the BHA adjuvant was cryopreserved at ⁇ 80° C. thawed immediately before use, and then used for immunization.
- the cholera toxin adjuvant (CTB) was prepared by mixing 1 ⁇ g of cholera toxin B subunit (Catalog No. 033-20611, Wako Pure Chemical Industries. Ltd.) and 1 ⁇ g of cholera toxin (Catalog No. 033-20621. Wako Pure Chemical Industries, Ltd.) for each mouse.
- the cholera toxin adjuvant was cryopreserved at ⁇ 80° C., thawed immediately before use, and then used for immunization.
- PBS( ⁇ ) was added to the mixture of 1 ⁇ g of split vaccine antigens with 20 ⁇ g of the BHA complex (BHA) adjuvant or with 2 ⁇ g of the cholera toxin adjuvant to adjust the amount of each vaccine preparation to 12 ⁇ l used for each mouse.
- the vaccine preparations were administered to 6-week-old mice through both nasal cavities in amounts of 6 ⁇ l each. Administration was carried out four times in total at intervals of 2 weeks (day 0, day 14, day 28, and day 42).
- mice were anesthetized using Ketalar (Daiichi Sankyo Company, Limited)/Selactar (Bayer), and blood samples were obtained from the orbital venous plexus.
- the sampled blood was allowed to stand at 4° C., overnight, and serum separation was carried out using a refrigerated benchtop centrifuge (9,100 g, 10 minutes, 4° C.).
- the obtained serum specimens were cryopreserved at ⁇ 20° C.
- IgG levels total IgG, IgG1, IG2a, and IG2c levels
- mice were anesthetized using Ketalar/Selactar 56 days after the initiation of immunization, exsanguinated via cardiopuncture, and euthanized. Immediately thereafter, nasal cavity lavages and bronchoalveolar lavages were sampled. Thereafter, the nasal cavity lavages and the bronchoalveolar lavages were stored on ice or refrigerated until ELISA assays were initiated.
- ELISA assays were carried out in the manner described below.
- the split vaccine antigens were applied to a plate at a concentration of 1 ⁇ g/ml (4° C. overnight), and blocking was carried out with 1% BSA/PBST (Tween 20: 0.5%) by allowing the plate to stand at room temperature for 2 hours.
- the serum sample was serially diluted using 1% BSA/PBST (Tween 20: 0.5%).
- HRP-labeled antibody in accordance with subclasses was used.
- OD was measured using a plate reader after coloring, and the amounts of influenza-antigen-specific antibody were calculated.
- FIG. 7 shows the results of measurement of the level of influenza-antigen-specific IgG in the sera (56 days after the initiation of immunization).
- the level of the antigen-specific antibody reactions in the sera induced in the group subjected to immunization with the BHA complex (BHA) adjuvant in combination with the influenza antigens was significantly higher than that induced in the group subjected to immunization with influenza antigens alone. Such phenomenon was observed in all the evaluated IgG subclasses.
- BHA BHA complex
- FIG. 8 shows the results of measurement of the amount of secretory IgA produced in the nasal cavity lavages and in the bronchoalveolar lavages.
- the amount of antigen-specific IgA production was high in the group subjected to immunization with the BHA complex (BHA) adjuvant in combination with the influenza antigens.
- BHA BHA complex
- secretory IgA production was not substantially observed in the group of mice subjected to immunization with influenza antigens alone.
- mice (6-week-old, female) were purchased from CLEA Japan. Inc. Mice were raised under SPF conditions.
- split vaccines The mouse-adapted A/Puerto Rico/8/34 (H1N1) split vaccines (hereafter referred to as “split vaccines”) received from Kitasato Daiichi Sankyo Vaccine Co., Ltd. were used as immunogens. During the experiment, antigens were refrigerated at 4° C. in the dark.
- the BHA complex (BHA) prepared in Example 1 or BHA1, BHA2, and BHA3 that are composing elements of the BHA complex were used as the adjuvant. Endotoxin content was determined by designating the standard for purification at 0.5 EU/ml or lower.
- the BHA adjuvant was cryopreserved at ⁇ 80° C., thawed immediately before use, and then used for immunization.
- the cholera toxin adjuvant (CTB) was prepared by mixing 1 ⁇ g of cholera toxin B subunit (Catalog No. 033-20611, Wako Pure Chemical Industries, Ltd.) and 1 ⁇ g of cholera toxin (Catalog No. 033-20621, Wako Pure Chemical Industries, Ltd.) for each mouse.
- the cholera toxin adjuvant was cryopreserved at ⁇ 80° C., thawed immediately before use, and then used for immunization.
- PBS( ⁇ ) was added to the mixture of 1 ⁇ g of split vaccine antigens and 20 ⁇ g each of the BHA complex (BHA) adjuvant, the BHA1 adjuvant, the BHA2 adjuvant, or the BHA3 adjuvant or 2 ⁇ g of the CTB adjuvant to adjust the amount of each vaccine preparation to 12 ⁇ l used for each mouse.
- the vaccine preparations were administered to 6-week-old mice through both nasal cavities in amounts of 6 ⁇ l each. Administration was carried out four times in total at intervals of 2 weeks (day 0, day 14, day 28, and day 42).
- mice were anesthetized using Ketalar (Daiichi Sankyo Company, Limited)/Selactar (Bayer), and blood samples were obtained from the orbital venous plexus.
- the sampled blood was allowed to stand at 4° C. overnight, and serum separation was carried out using a refrigerated benchtop centrifuge (9.100 g, 10 minutes. 4° C.).
- the obtained serum specimens were cryopreserved at ⁇ 20° C.
- IgG levels total IgG, IgG1, and IG2a levels
- mice were anesthetized using Ketalar/Selactar 56 days after the initiation of immunization, exsanguinated via cardiopuncture, and euthanized. Immediately thereafter, nasal cavity lavages and bronchoalveolar lavages were sampled. Thereafter, the nasal cavity lavages and the bronchoalveolar lavages were stored on ice or refrigerated until ELISA assays were initiated.
- ELISA assays were carried out in the manner described below.
- the split vaccine antigens were applied to a plate at concentration of 1 ⁇ g/ml (4° C., overnight), and blocking was carried out with 1% BSA/PBST (Tween 20: 0.5%) by allowing the plate to stand at room temperature for 2 hours.
- the serum sample was serially diluted using 1% BSA/PBST (Tween 20: 0.5%).
- HRP-labeled antibody in accordance with subclasses was used. After color had developed, OD was measured using a plate reader, and the amounts of influenza-antigen-specific antibody produced were measured.
- FIG. 9 shows the results of measurement of the level of influenza-antigen-specific IgG in the sera (56 days after the initiation of immunization).
- the level of the antigen-specific antibody reactions in the sera induced in the group subjected to immunization with the BHA complex (BHA) adjuvant in combination with the influenza antigens was significantly higher than that induced in the group subjected to immunization with influenza antigens alone.
- BHA BHA complex
- Such phenomenon was observed in all the evaluated IgG subclasses.
- antibody reactions in the sera were not significantly potentiated, compared with the group subjected to immunization with the influenza antigens alone.
- FIG. 10 shows the results of measurement of the amount of secretory IgA in the nasal cavity lavages and in the bronchoalveolar lavages.
- the amount of antigen-specific IgA was significantly higher in the group subjected to immunization with the BHA complex (BHA) adjuvant in combination with the influenza antigens than in the group subjected to immunization with the influenza antigens alone.
- BHA BHA complex
- the amount of secretory IgA was not significantly increased in the group subjected to immunization with the BHA1, BHA2, or BHA3 adjuvants that are composing elements of the BHA complex in combination with the influenza antigens, compared with the group subjected to immunization with the influenza antigens alone.
- BHA BHA complex
- the present invention is applicable in the field of production of a mucosal adjuvant and a mucosal vaccine preparation comprising such adjuvant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-265532 | 2012-12-04 | ||
JP2012265532 | 2012-12-04 | ||
PCT/JP2013/081459 WO2014087849A1 (fr) | 2012-12-04 | 2013-11-15 | Adjuvant pour vaccin pour membrane muqueuse |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/081459 A-371-Of-International WO2014087849A1 (fr) | 2012-12-04 | 2013-11-15 | Adjuvant pour vaccin pour membrane muqueuse |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/223,566 Continuation US9662386B2 (en) | 2012-12-04 | 2016-07-29 | Adjuvant for mucosal vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150306214A1 true US20150306214A1 (en) | 2015-10-29 |
Family
ID=50883272
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/649,279 Abandoned US20150306214A1 (en) | 2012-12-04 | 2013-11-15 | Adjuvant for mucosal vaccine |
US15/223,566 Active US9662386B2 (en) | 2012-12-04 | 2016-07-29 | Adjuvant for mucosal vaccine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/223,566 Active US9662386B2 (en) | 2012-12-04 | 2016-07-29 | Adjuvant for mucosal vaccine |
Country Status (5)
Country | Link |
---|---|
US (2) | US20150306214A1 (fr) |
EP (1) | EP2929893B1 (fr) |
JP (1) | JP6230028B2 (fr) |
TW (1) | TW201427687A (fr) |
WO (1) | WO2014087849A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662386B2 (en) * | 2012-12-04 | 2017-05-30 | Osaka University | Adjuvant for mucosal vaccine |
US20170196970A1 (en) * | 2014-06-04 | 2017-07-13 | Osaka University | Adjuvant for mucosal vaccine |
US11230701B2 (en) | 2014-06-27 | 2022-01-25 | Osaka University | Mutant hemagglutinin complex protein, and method for culturing pluripotent stem cells using same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類b肝病毒顆粒作為佐劑的疫苗組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
JP4817625B2 (ja) | 2003-08-11 | 2011-11-16 | 一般財団法人阪大微生物病研究会 | 粘膜免疫誘導アジュバントを含む新規ワクチン |
KR20050073865A (ko) | 2004-01-12 | 2005-07-18 | 대한민국(전남대학교총장) | 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제 |
JP2009081997A (ja) | 2007-09-27 | 2009-04-23 | Chemo Sero Therapeut Res Inst | ボツリヌス毒素成分haを核酸の細胞内導入キャリアーとして利用する方法 |
JP2009132686A (ja) | 2007-10-26 | 2009-06-18 | Okayama Univ | ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法 |
EP2929893B1 (fr) * | 2012-12-04 | 2020-10-14 | Osaka University | Adjuvant pour vaccin pour membrane muqueuse |
-
2013
- 2013-11-15 EP EP13860873.2A patent/EP2929893B1/fr active Active
- 2013-11-15 WO PCT/JP2013/081459 patent/WO2014087849A1/fr active Application Filing
- 2013-11-15 JP JP2014551032A patent/JP6230028B2/ja not_active Expired - Fee Related
- 2013-11-15 US US14/649,279 patent/US20150306214A1/en not_active Abandoned
- 2013-11-15 TW TW102141652A patent/TW201427687A/zh unknown
-
2016
- 2016-07-29 US US15/223,566 patent/US9662386B2/en active Active
Non-Patent Citations (2)
Title |
---|
Amatsu et al (Journal of Biological Chemistry Vol. 288, No. 49, pp 35617-35625, 2013) * |
Nakajima et al (Microbiol. Immunol. Vol. 42 (9), pp 599-605, 1998) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662386B2 (en) * | 2012-12-04 | 2017-05-30 | Osaka University | Adjuvant for mucosal vaccine |
US20170196970A1 (en) * | 2014-06-04 | 2017-07-13 | Osaka University | Adjuvant for mucosal vaccine |
US10226529B2 (en) * | 2014-06-04 | 2019-03-12 | Osaka University | Adjuvant for mucosal vaccine |
US11230701B2 (en) | 2014-06-27 | 2022-01-25 | Osaka University | Mutant hemagglutinin complex protein, and method for culturing pluripotent stem cells using same |
Also Published As
Publication number | Publication date |
---|---|
EP2929893B1 (fr) | 2020-10-14 |
JPWO2014087849A1 (ja) | 2017-01-05 |
EP2929893A1 (fr) | 2015-10-14 |
TW201427687A (zh) | 2014-07-16 |
US20160324960A1 (en) | 2016-11-10 |
JP6230028B2 (ja) | 2017-11-15 |
WO2014087849A1 (fr) | 2014-06-12 |
US9662386B2 (en) | 2017-05-30 |
EP2929893A4 (fr) | 2016-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McNeela et al. | A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery | |
US9662386B2 (en) | Adjuvant for mucosal vaccine | |
US9795664B2 (en) | Vaccine against streptococcal infections based on recombinant proteins | |
Rivera-Hernandez et al. | Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS) | |
Wei et al. | Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99 | |
Keijzer et al. | Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion | |
Tejera-Alhambra et al. | New biological insights in the immunomodulatory effects of mucosal polybacterial vaccines in clinical practice | |
US10226529B2 (en) | Adjuvant for mucosal vaccine | |
Shi et al. | The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization | |
Zhu et al. | Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin | |
US9119803B2 (en) | Carious tooth vaccine and preparation method | |
Gartner et al. | Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A | |
Jun et al. | Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication | |
Gursel et al. | Use of CpG oligonucleotides as mucosal adjuvants | |
KR20210141623A (ko) | 점막 면역원성의 조절 방법 | |
Mann et al. | CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice | |
Sloat et al. | Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice | |
Ikeda et al. | Comparison of mucosal immune response after oral, nasal or sublingual immunization with an outer membrane protein of Porphyromonas Gingivalis | |
Silvestre et al. | Display of FliC131 on the Surface of Lactococcus lactis as a Strategy to Increase its Adjuvanticity for Mucosal Immunization | |
KR20240031857A (ko) | Covid-19 백신을 임베딩하기 위한 파상풍 백신 플랫폼 | |
Tsai et al. | Mucosal vaccine delivery | |
WO2024050452A2 (fr) | Compositions et procédés pour augmenter des réponses immunitaires à des bactéries à gram négatif | |
Oh et al. | Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency | |
Kurkure et al. | Differential Requirements for Protection | |
Olivera et al. | Research Article Immunization with the Recombinant Cholera Toxin B Fused to Fimbria 2 Protein Protects against Bordetella pertussis Infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OSAKA UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJINAGA, YUKAKO;MATSUMURA, TAKUHIRO;YUTANI, MASAHIRO;AND OTHERS;REEL/FRAME:035774/0546 Effective date: 20150512 Owner name: DAIICHI SANKYO COMPANY, LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJINAGA, YUKAKO;MATSUMURA, TAKUHIRO;YUTANI, MASAHIRO;AND OTHERS;REEL/FRAME:035774/0546 Effective date: 20150512 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |